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SB-253514Lipopeptides (LPs) are a structurally diverse class of amphipathic natural products that were in the past
mainly known for their surfactant properties. However, the recent discovery of their antimicrobial and
cytotoxic bioactivities have fueled and renewed the interest in this compound class. Propelled by the
antimicrobial potential of this compound class, in this study a range of six underinvestigated LPs from
Pseudomonads were examinedwith respect to their antibiotic activities towards bacteria. The assays revealed
that only the glycosylated lipodipeptide SB-253514, produced by Pseudomonas strain SH-C52, showed
signiﬁcant antibacterial activity. Since the bioactivity of LPs is commonly attributed to membrane
interactions, we analyzed the molecular interactions between the LPs and bacteria-like lipid model
membranes in more detail via complementary biophysical approaches. Application of the quartz crystal
microbalance (QCM) showed that all LPs possess a high binding afﬁnity towards the model membranes.
Despite their similar membrane afﬁnity, monolayer studies displayed different tendencies of LPs to
incorporate into the membrane. The degree of membrane incorporation could be correlated with speciﬁc
structural features of the investigated LPs, such as distance between the peptidic macrocycle and the fatty
acid, but did not fully reﬂect their respective antibacterial activity. Cyclic voltammetry (CV) experiments
further demonstrated that SB-253514 showed no membrane permeabilization effects at inhibitory
concentrations. Collectively, these results suggests that the antibacterial activity of SB-253514 cannot be
explained by an unspeciﬁc detergent-like mechanism generally proposed for amphiphilic molecules but
instead appears to occur via a deﬁned structural target.al Biology, University of Bonn,
676; fax: +49 228 73 3250.
).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Bacterial lipopeptides (LPs) consist of a charged linear or cyclic
peptide head and a hydrophobic fatty acid tail of variable length. These
amphipathic molecules are predominantly produced by soil bacteria,
e.g. actinomycetes, bacilli or pseudomonads and are supposedly
secreted to fulﬁll a suite of natural functions, e.g. host defense,
enhancement of cell motility and bioﬁlm formation [1]. Since a number
of LPs of microbial origin was reported to possess antibacterial activity,
LPs represent a promising class of natural products with antibiotic
properties [2,3]. The prospect of this compound class in the ﬁeld of
antibiotics is also underlined by two LPs that reached already the drugmarket, i.e. the polymyxins and the recently approved daptomycin
(Cubicin®) [4].
LPs from Pseudomonas species are usually composed of an
unbranched-3-hydroxy fatty acid tail linked to a short oligopeptide
(2–25 amino acids) which is usually cyclized to form a lactone ring.
The presence of D-conﬁgurated amino acids and the occurrence of
non-proteinogenic amino acids, e.g. homoserine, 4-chloro-threonine
or diaminobutyric acid is particularly noteworthy. Based on the
number, type, and conﬁguration of the amino acids in the peptide
moiety, LPs of Pseudomonas spp. were classiﬁed into nine major
groups [5–8]. Most of the LPs obtained from Pseudomonads have been
tested for their surfactant activity or, in a phytopathological context,
assayed for their antifungal properties or their involvement in
virulence. However, these LPs have been scarcely investigated for
their potential to inhibit the growth of bacteria [2]. Antibacterial
properties were reported only for some members from four out of the
nine major LP groups: LPs of the viscosin [9,10], syringomycin [11,12],
tolaasin [13,14] and syringopeptin [15,16] group were shown to be
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megaterium, Staphylococcus aureus or Mycobacterium tuberculosis).
Particularly the antimycobacterial activity gained increasingly impor-
tance over time since more and more M. tuberculosis strains show
resistance towards standard treatment [17,18], which impressively
underlines the need for new antibiotics. Based on these promising
activities, we explored the antibacterial properties of those LPs from
Pseudomonads that were related to the nine amino acid containing
antimycobacterial LPs but which have not yet been investigated.
After evaluation of their antibiotic properties, we investigated the
molecular interactions between the selected LPs and lipid model
membranes because it is widely accepted that the primary target of
LPs is the cytoplasmic membrane. The main destructive action of LPs
on cell membranes has been referred to their unspeciﬁc detergent-
like activity, i.e. their ability to disintegrate the lipid bilayer [10,19,20].
However, more speciﬁc mechanisms, e.g. inhibition of the synthesis of
cell wall components [21], have also been demonstrated for some LPs.
Considering that the activities of Pseudomonas LPs appear to be
directed mainly towards Gram-positive bacterial competitors, we
designed a model membrane system to mimic properties of the natural
bilayer membrane of Gram-positives. To gain deeper insight into their
biological activities, the interaction of the selected LPs was studied in
detail via the following complementary biophysical methods:
1. The quartz crystal microbalance (QCM) was employed to investi-
gate the intensities and kinetics of LP binding towards supported
lipid bilayers. This technique provides time-resolved measure-
ments of mass changes adsorbed at the model membranes and
thereby allows the determination of kinetic binding constants of
the LPs.
2. The cyclic voltammetry (CV) was used to detect changes in
membrane permeability, e.g. pore formation induced by an interac-
tion between the LPs and membranes.
3. Finally, the subphase-assaywas used to obtain information about the
surface activity, i.e. the capacity of the LP to insert into a phospholipid
monolayer by detection of increased lateral membrane surface
pressure.
Using these techniques, we addressed the questions, whether LPs
affect the structure of model membranes and if this could explain
their antibacterial activities. To get a better insight into these activities
and affecting parameters, the impact of membrane constituents
(ergosterol content) and different sizes of the peptidic moiety of the
LPs was investigated in depth.
2. Materials and methods
2.1. Chemicals
The LP syringomycin Ewaspurchased fromSigmaAldrichChemicals,
Deisenhofen, Germany and used as supplied. All chemicals for model
membrane preparation were commercially available and used without
further puriﬁcation. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) and 1,2-Dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) were
purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Ergosterol
and hexadecanethiol were purchased from Sigma.
2.2. Bacterial producer strains and culture conditions
The LP producer strains Pseudomonas ﬂuorescens Pf-5 [22]
(orfamide A), Pseudomonas sp. MIS38 [23] (arthrofactin), and
Pseudomonas entomophila [24] (entolysin B) were kindly provided
by Prof. Loper (USDA/Oregon State University, Corvallis, USA), Prof.
Morikawa (Hokkaido University, Sapporo, Japan) and Dr. Vallet-Gely
(Centre de Génétique, CNRS, Gif-sur-Yvette, France), respectively.
Pseudomonas sp. SH-C52 (SB-253514) and P. ﬂuorescens SS101 [25]
(massetolide A) are isolates by one of the authors (J.M.R).P. ﬂuorescens SS101 was cultivated as previously described [26]. All
other strains were grown ﬁrst in 10 mL Davis Minimal Broth without
dextrose containing20 mMglycerol (DMBgly) in 50 mLFalcon tubes for
24–48 h at room temperature with shaking (100 rpm) using a Gerhardt
LS30horizontal shaker. Five 5000 mLErlenmeyerﬂasks containing1.5 L
DMBgly were inoculated with 2 mL starter culture. Cultures were
incubated for 72 h at 26 °Cwith shaking at 140 rpmusing an INFORS HT
Multitron incubator shaker.
2.3. Isolation and puriﬁcation of the lipopeptides
Massetolide A [26] and orfamide A [6] were puriﬁed as previously
described. The remaining three LPs were obtained according the
following procedure: the fermentation broths were acidiﬁed to pH 2
and portions (0.5 L) of the broths were extracted two times with 0.5 L
ethyl acetate to yield crude extracts. Further fractionation of each
extract by RP-SPE (J.T. Baker Bakerbond C18, 2 g) using stepwise
gradient elution with MeOH/H2O (40:60) to 100% MeOH yielded ﬁve
to six subfractions. 1H NMR proﬁling indicated subfractions of further
interest due to three clusters of resonances typical for peptides:
exchangeable downﬁeld amide signals, α-proton resonances and side
chain protons. Puriﬁcation of these subfractions by RP-HPLC using a
linear gradient of 70:30–100:00MeOH/H2O (0.05% TFA) over a period
of 65 min (Phenomenex Luna, 250×10 mm, 5 μm in combination
with a Phenomenex SecurityGuard Luna, 10×10 mm precolumn;
2 mL/min ﬂow rate; UV monitoring at 215 nm), yielded pure SB-
253514 or arthrofactin, respectively. Entolysin B was obtained in this
way only in a semi-pure form and had to be rechromatographed two
times by RP-HPLC in order to be considered a pure compound as
judged by LC-MS.
2.4. Detection of antibacterial activity
The antibacterial activity was determined by agar diffusion assays.
Culture plates (5% sheep blood Columbia agar, BD) were overlaid with
3 mL tryptic soy soft agar, inoculatedwith TSB (tryptic soy broth, Oxoid)
growthsuspensionof the bacteria to be tested. Compoundswerediluted
with DMSO to a concentration of 1 mg/mL (syringomycin E 0.5 mg/mL)
and 3 μL of this dilution were placed on the surface of the agar; the
diameter of the inhibition zone was measured after 24 h incubation at
37 °C. The indicator strains represent clinical isolates from distinct
patients as well as standard laboratory strains and are listed in Table 1.
The strains weremaintained onMueller–Hinton (MH) agar or on blood
agar.
MICdeterminationswere carriedout inmicrotiter plates.Arthrobacter
crystallopoietes DSM 20117 was grown in tryptic soy broth (Oxoid), all
other strains were grown in half-concentrated Mueller–Hinton broth
(Oxoid). MICs with serial twofold dilution steps were performed (1:2).
Bacteriawere added togive aﬁnal inoculumof 105 CFU/ml in a volumeof
0.2 mL. After incubation for 24 h at 37 °C, theMICwas read as the lowest
compound concentration causing inhibition of visible growth. Results are
mean values of three independent determinations. Since some lipopep-
tides were previously reported to possess a calcium dependency for
optimum activity [27], the effect of calcium substituted medium on the
MICs was evaluated. Two organisms, S. aureus SG511 and Bacillus subtilis
168 were used in the test which consisted of a broth dilution MIC
determination in supplemented (0.2 mg/mLCaCl2) andunsupplemented
half-concentrated Mueller–Hinton broth.
2.5. Model membrane preparation
Cleaning and preparation procedures of the quartz sensors for QCM
and CV were already described previously [28]. The supported bilayers
were formed by transferring a monolayer consisting of either POPC/
DOPG (9/1), POPC/DOPG/ergosterol (6/1/3) or POPC/DOPG/ergosterol
Table 1
Antimicrobial disk diffusion inhibitory activities of the investigated Pseudomonas-lipopeptides.
Organism Zone of inhibition (mm)
SB-253514 Massetolide A Syringomycin E Orfamide A Arthrofactin Entolysin B
Gram-positive bacteria
Staphylococcus aureus SG 511 3 0 0 0 0 0
Staphylococcus aureus 5185 (MS)a 3 0 0 0 0 0
Staphylococcus aureus LT-1334 (MR)a 0 0 0 0 0 0
Staphylococcus epidermidis LT-1324 (MR)a 0 0 0 0 0 0
Staphylococcus epidermidis ATCC 12228 0 0 0 0 0 0
Staphylococcus simulans 22 0 0 0 0 0 0
Micrococcus luteus ATCC 1856 0 0 0 0 0 0
Enterococcus faecium I-11305b 0 0 0 0 0 0
Bacillus subtilis 168 4 0 0 0 0 0
Bacillus megaterium 0 0 0 0 0 0
Listeria welchimeri DSM 20650 3 0 0 0 0 0
Corynebacterium pseudodiphtheriticum 3 0 0 0 3 0
Corynebacterium diphtheriae 3 0 0 0 3 0
Corynebacterium xerosis Va 167198 3 0 0 0 3 0
Mycobacterium smegmatis ATCC 70084 3 0 0 0 3 0
Arthrobacter crystallopoietes DSM 20117 13 8 5 0 4 3
Gram-negative bacteria
Escherichia coli DH5 alpha 0 0 0 0 0 0
Escherichia coli O-19592 0 0 0 0 0 0b
Klebsiella pneumonia I-10910 0 0 0 0 0 0
Citrobacter freundii I-11090 0 0 0 0 0 0b
Pseudomonas aeruginosa I-10968 0 0 0 0 0 0
Serratia marcescens 0 0 0 0 0 0
a MS = methicillin-susceptible; MR = methicillin-resistant.
b Diffuse inhibition zone of 2 mm visible.
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ﬁxed ﬁrst monolayer of hexadecanethiol.
2.6. Biophysical methods
QCM experiments were performed at 25 °C using the LiquiLab21
system (ifak e.V., Barleben, Germany). After reaching a constant
frequency, 3 mL of a 0.5 μM peptide solution were injected into the
ﬂow system. The runwas stopped after reaching a constant frequency.
The binding constants were calculated from the frequency traces as
described before [29].
CV experiments to detect membrane barrier disturbances have
already been described [29]. LP solution (0.5 μM)was injected into the
CV chamber after completing 35 scans. Potential current changes
were calculated from the CV curves by integrating each complete
cycle.
For themonolayer subphase-assay the phospholipid mixtures were
spread on a Langmuir trough ﬁlled with ultra-pure water. After
recovery for 15 min, the monolayer was compressed to 1/2–2/3 of the
collapse pressure. Five injections of each 0.1 μM LP (ﬁnal concentra-
tion 0.5 μM) into the aqueous subphase at intervals of at least two
minutes were monitored in real time by changes in the lateral surface
pressure.
The logP values for the six lipopeptides were estimated by using
the ACD-LogD-Suite 5.0 software and are given in Fig. 1.
3. Results
3.1. Selection criteria for LPs
To date, all LPs of Pseudomonads that have been investigated for
antibacterial activity represent either 9- or 22-amino acid (AA)-
containing cyclic LPs. Based on and inspired by the antimycobacterial
activity of the 9-AA-containing LPs of the viscosin and syringomycin
class, we wanted to probe the chemical space around these molecules.
To this end, we included the 2-AA-containing SB-253514 [8], the 10-
AA-containing orfamide A [6], the 11-AA-containing arthrofactin andthe 14-AA-containing entolysin B [7] in this study (Fig. 1). These LPs
possess special features like glycosylation, different cyclization
schemes, and different fatty acid chain lengths. Each of these LPs has
not been examined for antibacterial properties yet, either due to
paucity of available material or because the substance class was
discovered only recently. SB-253514 represents the smallestmember of
the Pseudomonas-LP family. Its biosynthesis pathway unambiguously
groups it with this compound class; however, its peptide moiety is
rearranged to a cyclocarbamate structure during biosynthesis (J.M.R.
and H.G., unpublished). Furthermore, it is the only Pseudomonas-LP
known so far with a glycosylated 3-hydroxy-fatty acid side chain.
Arthrofactin was originally isolated from a bacterium of the genus
Arthrobacter [23], however its taxonomic classiﬁcationwas later revised
to Pseudomonas sp. MIS38 [30]. Therefore, arthrofactin is now
considered a true Pseudomonas-LP. Additionally, there was confusion
about the structure of arthrofactin, since two versions of the molecule
were reported in the literature, differing in the cyclization scheme and
stereochemistry [23,31]. We reinvestigated this compound spectro-
scopically and corrected the structure as depicted in Fig. 1 (details of the
structure revision will be published elsewhere). Massetolide A and
syringomycin E were included as reference compounds and to deduce
possible structure-activity relationships.
3.2. Antibacterial activity of LPs
The effect of all LPs on the growth of a large collection of bacterial
genera and species is shown in Table 1. In general, only Gram-positive
bacteria were affected by the six investigated LPs. All tested LPs
displayed inhibitory activities against A. crystallopoietes. In addition,
arthrofactin was observed to moderately inhibit the growth of
Corynebacteria and a mycobacterial strain. The antibacterial activities
of SB-253514 paralleled those of arthrofactin, but were stronger
against A. crystallopoietes and additionally affected staphylococci,
bacilli and Listeria. The MIC values of the LPs showed a good
correlation with the respective inhibition zones, obtained from the
agar-diffusion assay. However, this analysis also revealed that only
SB-253514, massetolide A and entolysin B displayed signiﬁcant
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Fig. 1. Chemical structures of the investigated lipopeptides. Abbreviations: Dab= 2,4 diaminobutyric acid, Dhb= 2,3-dehydroaminobutyric acid. All other amino acids are identiﬁed
by standard three-letter biochemical notation. The absolute conﬁguration of each amino acid is indicated by the following stereodescriptors: D/L, E/Z, a= allo, t= threo. The absolute
conﬁguration of entolysin B has not been determined. Gray boxes indicate amino acids with chargeable side chains. Basic amino acids (Dab, Arg) were positively charged
(protonated) under the test conditions of the model membrane assays (pH 5.5). Acidic amino acids (Asp, Glu) were not affected by the given pH and remained neutral. The logP
values were estimated as follows: SB-253514 (+5.21), massetolide A (−2.26), syringomycin E (−9.24), orfamide A (−0.50), arthrofactin (−3.86), entolysin B (−2.69).
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20117 and Corynebacterium xerosis Va 167198, respectively (Table 2).
Since it became recently evident that some LPs heavily depend on the
presence of Ca2+ ions for full antibacterial activity [27], all Pseudomonas-
LPs of this studywere also re-tested for their antibacterial activity in the
presence of CaCl2. However, for all tested lipopeptides no increase in
potency was observed in the presence of added calcium (data not
shown).3.3. Membrane binding afﬁnity of LPs
Since LPs generally display surfactant properties, one might
associate their antibiotic activity with the capacity to interact with
the bacterial membranes. This capacity should mainly be reﬂected by
the binding afﬁnity of the peptides towards the membrane. Quartz
crystal microbalance (QCM) was applied to determine the constants
(association rate kass, dissociation rate kdiss, overall binding afﬁnity
kD) of the six LPs binding to model membranes. The lipid composition
was adjusted to imitate the predominant membrane components of
Gram-positive bacteria and mycobacteria. POPC was used as the main
phospholipid representing the most common fatty acid in bacterial
membranes (C16:0 and C18:1) [32–35]. Although PGs are more
common in bacterial membranes than PCs, we consciously decided to
use PCs as main components (for stability reasons) and added
10 mol% DOPG to confer a net negative charge to the membranes. All
bacteria possess membrane stabilizing hopanoids. The activity ofTable 2
Antimicrobial minimal inhibition concentrations (MICs) of the investigated Pseudomonas-li
Organism MIC (μg/mL)
SB-253514 Arthrofactin
Staphylococcus aureus SG 511 25 N50
Bacillus subtilis 168 12.5 50
Listeria welchimeri DSM 20650 25 N50
Corynebacterium xerosis Va 167198 50 50
Mycobacterium smegmatis ATCC 70084 50 N50
Arthrobacter crystallopoietes DSM 20117 12.5 50these sterol-like components were simulated by adding certain
fractions of ergosterol (either 30 mol% or 50 mol%).
All LPs displayed considerable high overall binding afﬁnities to the
three different types of model membranes (Fig. 2), which are in the low
micromolar or high nanomolar range (2.22×10−7–1.28×10−6 M).
Considering the kD values (Fig. 2A), ergosterol has obviously no
signiﬁcant inﬂuence on the peptide binding intensities. The QCM
technique allows for a detailed view on the association and dissociation
rates of the peptides. Fig. 2B and C reveal that the high afﬁnities of the LPs
mainly result from rapid association rates (3589–8777 M−1 s−1),
whereas the dissociation rates are in a median range. It is worth
mentioning that the binding afﬁnity of SB-253514 is slightly lower
compared to the other LPs mainly due to a diminished association rate.3.4. Membrane incorporation of LPs
The rapid and comparable association rates of the LPs binding to
membranes could suggest that besides the polar interaction of the
peptide with the phospholipid head group, a membrane insertion is
dominant. An insertion of the lipid chains of the LPs into bacterial
membranes could induce antibacterial effects by changing the lateral
distribution and function of membrane components, such as carriers
of cell wall precursors.
In this study, we performed a monolayer subphase assay to
investigate whether the LPs in general are able to incorporate into the
membrane and to quantify this capacity for a correlation with theirpopeptides.
Massetolide A Syringomycin E Entolysin B Orfamide A
N50 50 N50 N50
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Fig. 2. Kinetic constants of lipopeptide binding afﬁnities to model membranes.
(A) Independent on the model membrane composition (POPC/DOPG/ergosterol in
different ratios), all lipopeptides display strong binding afﬁnities (kD) in the lower
micromolar range comparable to that of target-mediated membrane interaction of other
antibiotic active peptides. These high afﬁnities mainly result from rapid association rates
kass (B), whereas the dissociation rates kdiss (C) are in a median range.
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6/1/3; 4/1/5, molar ratio, resp.) were spread on the surface of a water
ﬁlled Langmuir trough. After lateral compressing the monolayer,
0.1 μM peptide solutions were injected into the subphase, repeatedly
for ﬁve times each after reaching an equilibrated surface pressure.
Changes in the surface pressure were monitored in real time. An
example for LP injection into the aqueous subphase and the time
course of the resulting changes in lateral surface pressure of themonolayer is given in Fig. 3A. It is evident that each injection further
increases the surface pressure which can be related to the extent of
peptide incorporation into the membrane, reaching a saturation
around the highest concentration of 0.5 μM. Overall Δp represents the
total increase in surface pressure after ﬁve injection (0.5 μM) and can
thus be regarded as the degree of membrane insertion capacity of
each of the LPs (Fig. 3B).
In contrast to the QCM data, differences in the extent of
incorporation became obvious. Orfamide A and entolysin B had the
highest tendency for membrane incorporation, followed by masseto-
lide A, arthrofactin, and SB-253514. However, syringomycin E had
only a minor tendency to insert into themembrane.With exception of
arthrofactin and entolysin B showing slightly decreased Δp values
with increasing amounts of ergosterol, the general tendency of
peptide monolayer insertion appears to occur relatively independent
on membrane composition. On a ﬁrst view, these data do not directly
reﬂect the binding afﬁnity data and need further discussion with
respect to the structural features of the peptides.
3.5. Membrane permeabilization effects of LPs
The subphase data cannot explain the different antibacterial
activities of the LPs. However, membrane insertion of the LPs could
be regardedas a prerequisite formodifying themembranepermeability
in light of the already reported membrane disintegrating activities of
some LPs [36]. To focus on this feature, we applied a cyclic voltammetry
(CV) assay in combination with the model membranes used. By
detecting changes in Faradaic currents after peptide addition, this
technique allows for the determination of membrane permeability
changes. However, it is not possible to differentiate between unspeciﬁc
membrane permeabilization and formation of deﬁned pores. To
compare the CV with the QCM data and refer to the saturation
concentration in the subphase assay, 0.5 μMpeptide solutionwas used.
For all LPs it became evident that the addition of 0.5 μM peptide
solution did not lead to any permeabilization of themodelmembranes,
independent of the membrane composition (data not shown).
To investigate whether higher and MIC relevant concentrations
induce permeability changes, we selected the most effective LP SB-
253514 and repeated the CV experiments at concentrations repre-
senting two-, four- and tenfold its MIC (25; 50; 125 μg mL−1).
Furthermore, orfamide A, massetolide A, and arthrofactin were also
analyzed for their permeabilization ability in the MIC relevant range
(50 μg mL−1) and compared with syringomycin E as a reference,
which is known for pore formation in concentrations explicitly above
0.5 μM. Since data from Dalla Serra and coworkers [37] pointed out
the positive inﬂuence of sterols for membrane permeabilization, we
used amodel membrane composed of POPC/DOPG/ergosterol (4/1/5).
As expected, syringomycin E permeabilized the membrane at
concentrations comparable to its MIC (40.8 μM), which became
evident by an increased Faradaic current by 71%. In contrast, SB-
253514 did not show any increase in the Faradaic current, neither at
45 μM (twofold MIC), 90 μM (fourfold MIC) nor at 225 μM (tenfold
MIC) indicating that membrane permeabilization is obviously not the
key to explain the bactericidal activity of this glycosylated lipodipep-
tide. The other three LPs tested did not show effects on the membrane
barrier function at MIC concentrations, which was partly surprising as
discussed below.
4. Discussion
4.1. Antibacterial activity of the LPs
Consistent with previous observations [10,14–16], none of the
Gram-negative bacterial species tested were inhibited in growth by the
six Pseudomonas-LPs investigated here. This lack of activity of many LPs
againstGram-negative bacteria has beenascribed toprotective effects of
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Fig. 3.Membrane incorporation of the lipopeptides detected by Langmuir monolayer assay. A) Each lipopeptide injection further increases the lateral surface pressure which can be
related to the extent of peptide incorporation into the membrane, reaching saturation around the highest concentration. B) Overall Δp represents the total increase in surface
pressure after ﬁve injection (0.5 μM). The amount of membrane incorporation differs within the six lipopeptides and can be related to their structure, as discussed in detail.
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resistance for the likewise Gram-negative LP-producing Pseudomonads
[38]. The antibacterial activity observed in agar-diffusion assays
conﬁrmed in general the antibacterial potential of Pseudomonas-LPs
towards enterococci [10], micrococci [15], staphylococci [10,16], bacilli
[12–16] and mycobacteria [9,16,11]. However, the activities against
Listeria, corynebacteria and an Arthrobacter species observed in this
study have not been reported so far. Surprisingly, syringomycin E,
known to be active towards B. megaterium (MIC=5 μM, [12]) and
Mycobacterium smegmatis (MIC=1.5 μg/mL, [11]), and massetolide A,
reported to be active against M. tuberculosis (MIC=5–10 μg/mL, [9])
and Mycobacterium avium-intracellulare (MIC=2.5–5 μg/mL, [9]),
showed no activity towards comparable indicator strains. These results
are not necessarily in contradiction, since others also demonstrated the
inactivity of syringomycin E towards B. megaterium (ITM100) [15] and,
in the case ofmassetolideA, anotherMycobacterium specieswas used as
test strain (M. smegmatis instead of M. tuberculosis or M. avium-
intracellulare). The absence of activity of syringomycin E against M.
smegmatismight be attributed to acquired resistance or species-speciﬁc
variations of this strain regarding the cell-surface or cell wall
composition [39,40].
Despite the literature reports, the observed antibacterial potential
deduced from the agar-diffusion assay, the overall activity of most of
the tested Pseudomonas-LPs have to be judged, according to their MIC
values, as weak to moderate. Solely, the LP SB-253514, most unusual
in structure, shows signiﬁcant MICs towards several Gram-positives.
4.2. LPs display high membrane afﬁnity
The different modes of peptide interaction with membranes, e.g.
peptide attachment to or incorporation into themembranes, aremainly
reﬂected by binding afﬁnity data. The QCM binding assay provided data
that conﬁrm a strong binding afﬁnity of all six LPs of this study to the
differently composed model membranes. The kD values in the low
micromolar or high nanomolar range are comparable to that of target-
mediated membrane interaction of other antibiotic active peptides. For
instance, the cyclic LP friulimicin, which consists of a cyclic decapeptide
N-terminally linked to an unsaturated branched fatty acid was recently
shown to bind membranes in presence of the bactoprenol target C55-P
with a kD value close to that of the LPs in this study (0.21±0.08 μM)
[41]. The membrane association rate of LPs, which even exceeds that of
friulimicin (3736±1983M−1 s−1), appears to be driven by two facts:
the polar amino acid residues initially allow for interaction with the
polar head groups of the phospholipids, followed by an incorporation ofthe fatty acids into the membrane core. Regarding the time frame of
QCM detection, one can postulate that QCM data mainly reﬂect the
peptidemembrane attachment since theprocessofmembrane insertion
and reorganization is too slow to be fully considered under the dynamic
ﬂow conditions. The dominance of the polar moiety for strong binding
afﬁnities could explain the lower afﬁnity of the dipeptide SB-253514
compared to the other derivatives possessing more polar regions.
Compared to all other investigated LPs in this study, the most lipophilic
SB-253514 (logP value of +5.21) is not able to associate to the
membrane in a similar amount. The predominant role of polar
interaction for peptide binding afﬁnity also accounts for the minor
impact of the different membrane compositions, which possesses
similar surface regions despite of differences in ﬂuidity.
Summarizing, QCM data showed a high membrane afﬁnity for all
tested LPs. However, there is no indication for differences in the
binding afﬁnity that might explain the differences in antibacterial
activities of the tested LPs.
4.3. LP membrane insertion depends on the LP structure but is not
related to antibacterial activity
Peptide incorporation into the membrane appears to be timely
subordinated to the peptide attachment and thus cannot completely
be detected by QCM. However, peptide insertion might be a serious
contribution to bactericidal activity, since membrane-inserted pep-
tides can possess a strong impact on bacterial membrane order and
transport processes, even without changing the general barrier
function.
The monolayer subphase assay allows investigating the incorpo-
ration process under equilibrium conditions. Regarding the extent of
peptide incorporation given by the change in lateral surface pressure,
the concentration of 0.5 μM appears to be near saturation since the
increases in pressure were strongly diminished with each further
injection. According to the absolute changes in pressure Δp, the
Pseudomonas-LPs can be subdivided into three groups in relation to
their structure.
Syringomycin E (SRE) appears unique with the lowest intensity for
membrane incorporation. To structurally explain this ﬁnding, the
peptide cycle ﬁrst) possesses three charged amino acids leading to a
distinct hydrophilic structure (logP value of −9.24) (Fig. 1) and is
therefore repulsed by the lipid portion of the bilayer membrane and
second) is directly linked to the fatty acid and thus could impede the
fatty acid to fully insert into the membrane, even though SRE attaches
to the membranes with high afﬁnity due to its polar amino acids.
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primarily the attachment of LPs to the membrane surface.
Entolysin B and orfamide A as a second group display the strongest
incorporation into the membranes. Although the fatty acid chain of
entolysin B is shorter than that of SRE, entolysin B has nine exocyclic
amino acids, which can act as a spacer between the cycle and the fatty
acid. Thus, the fatty acid is freely accessible for a membrane insertion
without steric restrictions by the ring which appears to be also
relevant for orfamide A.
The third group comprises SB-253514, arthrofactin and masseto-
lide A, which displayed a median incorporation tendency. Compared
to orfamide A, arthrofactin also possesses a two amino acid residue
spacer which separates the relative large cycle and the fatty acid.
However, the shorter fatty acid chain of arthrofactin (C10) compared
to orfamide A (C14) refers to a changed balance, which is also true for
massetolide A (C10).
Despite the different structure of SB-253514, the Δp value is
comparable to that of arthrofactin and massetolide A. SB-253514
bears a C14 fatty acid and possesses the smallest possible cycle with
two amino acid residues. One can speculate that such a peptide would
excellently integrate into the membrane even without a spacer part.
However, SB-253514 did not reach the Δp values of entolysin B and
orfamide A. It is conceivable that the sugar moiety linked to the
peptide impedes the complete incorporation of the fatty acid into the
membrane. However, although these structural discussions allow
interpreting the membrane insertion capacities of the LPs, they do not
suggest those non-targeted mechanisms as relevant contribution for
bactericidal activity.
In general, the amphipathic nature of LPs favors a certain impact
on the membrane barrier function. This is further supported by
studies showing syringomycin E [15,37,42] and other Pseudomonas
LPs including massetolide A [43], syringopeptins [15,37,42], syringo-
toxin [15,37,44], tolaasin I [19], entolysins A and B [7] andWLIP [19] to
be able to lyse red blood cells and partly to permeabilize model
membranes. Further SRE data suggested that membrane lysis and
pore formation occured at SRE concentrationsN0.5 μM, partly even at
concentrations above 40 μM [36,42,45–49]. Referring to Hutchison et
al. [36] syringomycin has to exceed a threshold concentration for
micelle formation to induce permanent pore formation, whereas SRE
in lower concentrations reversibly inserts into the membrane. Indeed,
we could also detect the inability of SRE at the low concentration of
0.5 μM to change the membrane barrier function, as all the other LPs
failed to show this efﬁciency, but in the MIC range SRE permeabilized
the membrane presumably by micelle formation.
In contrast, arthrofactin, orfamide A, and massetolide A were not
able to disrupt the POPC/DOPG/ergosterol membrane at MIC relevant
ranges (50 μg mL−1). In the case of massetolide A it was somewhat
surprising, since massetolide A is known for hemolytic activities. The
cause for this discrepancy should be related to the test systems.
Erythrocyte membranes are asymmetrically composed with respect to
charge and possess high intrabilayer exchange dynamics [50]. In
contrast, the model membranes used in this study are composed of a
ﬁxed ﬁrst layer and a well-regulated second layer representing a much
less dynamic system than e.g. the erythrocyte membrane that is
consequently not easily to permeabilize. However, it raises the question
whether SRE is able to permeabilize the POPC/DOPG/ergosterol
membrane at MIC concentrations whereas the other lipopeptides did
not. Regarding the SRE structure, this peptide contains a certain fraction
of positively charged amino acid residues (Fig. 1) which can induce a
stronger interaction with the negatively charged membrane and
membrane permeabilization although this can neither be correlated to
the binding kinetics nor the subphase data.
However, despite the peculiarities of the permeability assays,
unspeciﬁc membrane permeabilization appears not be a dominant
reason for the bactericidal activity, considering the activity spectrum
in Table 2 and focusing on the dipeptide SB-253514. The dipeptidedisplayed the best antibiotic activities in this study, but this activity
can also not be explained by a membrane permeabilization, even at
high and MIC exceeding concentrations. Other lipopeptides with
antibiotic activities comparable to SB-253514, e.g. MSI-843, displays
signiﬁcantmembranepermeabilization at peptide concentration clearly
beneath the MIC [51]. Consequently, other mechanisms have to be
involved in the SB-253514 activity. To date, for three groups of LPs two
major targets in Gram-positive microbes have been identiﬁed: the LPs
plusbacin A3 [52] and the calcium dependent friulimicin [21] interfere
with the cell wall biosynthesis by inhibition of peptidoglycan-synthesis
or complexation of the bactoprenol phosphate carrier C55-P, respec-
tively. In contrast to these extracellular targets, LPs of the ADEP class act
intracellularly by binding to the target enzyme ClpP [53] which leads to
dysregulation of the bacterial proteolytic machinery. Subtilosin A is
another example for a antimicrobial peptide, for which deﬁned target
structures are postulated to participate in activity additionally to non-
speciﬁc peptide-membrane interactions [54]. Whether SB-253514 acts
byoneof the abovementionedmechanismsor by anovelmodeof action
is the subject of future studies.
5. Conclusion
This study provides for the ﬁrst time a wide screening of antibiotic
activity for Pseudomonas lipopeptides. Probing the antibacterial poten-
tial of six structurally different LPs produced by Pseudomonads revealed
the glycosylated lipodipeptide SB-253514 as a promising antibacterial
compound, while the other tested LPs showed surprisingly no or poor
antibacterial activities. Subsequent membrane model studies gave
further insights and a clear indication for strong membrane activity of
a series of LPs. However, these investigations could not explain the
antibiotic activity of SB-253514 and the lack of activity of the other
Pseudomonas-LPs tested. Particularly intriguing is the ﬁnding that the
commonly observed unspeciﬁc cytoplasmic membrane permeabiliza-
tion capabilities of LPs, which usually affect membrane integrity and
cause leakage of ions from the cell, can be ruled out as antibacterial
mode of action of SB-253514. This study demonstrated that SB-253514
possesses most likely a speciﬁc mode of action, acting presumably via
deﬁned target structures and provided therefore the basis for further
mode of action studies.
Acknowledgements
We gratefully acknowledge M. Morikawa, Hokkaido University,
Japan and I. Vallet-Gely, Centre de Génétique, CNRS, Gif-sur-Yvette,
France for providing the strains P. sp. MIS38 and P. entomophila,
respectively. We appreciate the assistance of S. Kremer, A. Tiesler and
M. Stanova for culture optimization studies and semipreparative HPLC
isolation work, respectively. Special thanks are extended to C. Mantell
and A.M. Luebke for initial QCM- and CV-assays on the LPs, to H.
Falkenstein-Paul for excellent technical assistance and to M. Weigt for
performing logP calculations. This research was supported by the
Deutsche Forschungsgemeinschaft (DFG) grants GR 2673/2-1 (H. G.)
and BE 2242/3-1 (G. B.) and Sa292/13-1 (H.G.S.) within the ‘Research
Unit FOR854 — Post-Genomic Strategies for New Antibiotic Drugs and
Targets’.
References
[1] J.M. Raaijmakers, I. de Bruijn, O. Nybroe, M. Ongena, Natural functions of
lipopeptides from Bacillus and Pseudomonas: more than surfactants and
antibiotics, FEMS Microbiol. Rev. 34 (2010) 1037–1062.
[2] P. Singh, S.S. Cameotra, Potential applications of microbial surfactants in
biomedical sciences, Trends Biotechnol. 22 (2004) 142–146.
[3] H. Hashizume, Y. Nishimura, Cyclic lipopeptide antibiotics, in: Atta-ur-Rahman
(Ed.), Studies in Natural Products Chemistry, Vol. 35, Elsevier, Amsterdam, 2008,
pp. 693–751.
[4] G. Pirri, A. Giuliani, S.F. Nicoletto, L. Pizzuto, A.C. Rinaldi, Lipopeptides as anti-
infectives: a practical perspective, Cent. Eur. J. Biol. 4 (2009) 258–273.
573K. Reder-Christ et al. / Biochimica et Biophysica Acta 1818 (2012) 566–573[5] H. Gross, J.E. Loper, Genomics of secondary metabolite production by Pseudomonas
spp, Nat. Prod. Rep. 26 (2009) 1408–1446.
[6] H. Gross, V.O. Stockwell, M.D. Henkels, B. Nowak-Thompson, J.E. Loper, W.H.
Gerwick, The genomisotopic approach: a systematic method to isolate products of
orphan biosynthetic gene clusters, Chem. Biol. 14 (2007) 53–63.
[7] I. Vallet-Gely, A. Novikov, L. Augusto, P. Liehl, G. Bolbach, M. Péchy-Tarr, P. Cosson,
C. Keel, M. Caroff, B. Lemaitre, Association of Hemolytic activity of Pseudomonas
entomophila, a versatile soil bacterium, with cyclic lipopeptides production, Appl.
Environ. Microbiol. 76 (2010) 910–921.
[8] D.J. Busby, R.C.B. Copley, J.A. Hueso, S.A. Readshaw, A. Rivera, SB-253514 and
analogues: novel inhibitors of lipoprotein associated phospholipase A2 produced
by Pseudomonas ﬂuorescens DSM 11579, J. Antibiot. 53 (2000) 670–676.
[9] J. Gerard, R. Lloyd, T. Barsby, P. Haden, M.T. Kelly, R.J. Andersen, Massetolides A-H,
antimycobacterial cyclic depsipeptides produced by two Pseudomonads isolated
from marine habitats, J. Nat. Prod. 60 (1997) 223–229.
[10] D. Sinnaeve, C. Michaux, J. van Hemel, J. Vandenkerckhove, E. Peys, F.A.M.
Borremans, B. Sas, J. Wouters, J.C. Martins, Structure and x-ray conformation of
pseudodesmins A and B, two new cyclic lipodepsipeptides from Pseudomonas
bacteria, Tetrahedron 65 (2009) 4173–4181.
[11] E. Buber, A. Stindl, N.L. Acan, T. Kocagoz, R. Zocher, Antimycobacterial activity of
lipodepsipeptides produced by Pseudomonas syringae pv syringae B359, Nat. Prod.
Lett. 16 (2002) 419–423.
[12] A. Scaloni, M. Dalla Serra, P. Amodeo, L. Mannina, R.M. Vitale, A.L. Segre, O.
Cruciani, F. Lodovichetti, M.L. Greco, A. Fiore, M. Gallo, C. D'Ambrosio, M. Coraiola,
G. Menestrina, A. Graniti, V. Fogliano, Structure, conformation and biological
acitivity of a novel lipodepsipeptide from Pseudomonas corrugata: cormycin A,
Biochem. J. 384 (2004) 25–36.
[13] M.C. Emanuele, A. Scaloni, P. Lavermicocca, N.S. Jacobellis, L. Camoni, D. di Giorgio,
P. Pucci, M. Paci, A. Segre, A. Ballio, Corpeptins, new bioactive lipodepsipeptides
from cultures of Pseudomonas corrugata, FEBS Lett. 433 (1998) 317–320.
[14] C. Bassarello, S. Lazzaroni, G. Bifulco, P. Lo Cantore, N.S. Iacobellis, R. Riccio, L.
Gomez-Paloma, A. Evidente, Tolaasins A-E, ﬁve new lipodepsipeptides produced
by Pseudomonas tolaasii, J. Nat. Prod. 67 (2004) 811–816.
[15] P. Lavermicocca, N.S. Iacobellis, M. Simmaco, A. Graniti, Biological properties and
spectrum of activity of Pseudomonas syringae pv. syringae toxins, Physiol. Mol.
Plant Pathol. 50 (1997) 129–140.
[16] I. Grgurina, M. Bensaci, G. Pocsfalvi, L. Mannina, O. Cruciani, A. Fiore, V. Fogliano,
K.N. Sorensen, J.Y. Takemoto, Novel cyclic lipodepsipeptide from Pseudomonas
syringae pv. lachrymans strain 508 and syringopeptin antimicrobial activities,
Antimicrob. Agents Chemotherap. 49 (2005) 5037–5045.
[17] J.C. Sacchettini, E.J. Rubin, J.S. Freundlich, Drugs versus bugs: in pursuit of the
persistent predator Mycobacterium tuberculosis, Nature Rev. Microbiol. 6 (2008)
41–52.
[18] P.R. Donald, P.D. van Helden, The global burden of tuberculosis — combating drug
resistance in difﬁcult times, N. Engl. J. Med. 360 (2009) 2393–2395.
[19] M. Coraiola, P. Lo Cantore, S. Lazzaroni, A. Evidente, N.S. Iacobellis, M. Dalla Serra,
WLIP and tolaasin I, lipodepsipeptides from Pseudomonas reactans and Pseudo-
monas tolaasii, permeabilise model membranes, BBA 1758 (2006) 1713–1722.
[20] C. Carrillo, J.A. Teruel, F.J. Aranda, A. Ortiz, Molecular mechanism of membrane
permeabilization by the peptide antibiotic surfactin, BBA 1611 (2003) 91–97.
[21] T. Schneider, K. Gries, M. Josten, I. Wiedemann, S. Pelzer, H. Labischinski, H.G. Sahl,
The lipopeptide antibiotic friulimycin B inhibits cell wall biosynthesis through
complex formation with bactoprenol phosphate, Antimicrob. Agents Chemother.
53 (2009) 1610–1618.
[22] I.T. Paulsen, C.M. Press, J. Ravel, D.Y. Kobayashi, G.S.A. Myers, D.V. Mavrodi, R.T.
DeBoy, R. Seshadri, Q. Ren, R. Madupu, R.J. Dodson, A.S. Durkin, L.M. Brinkac, S.C.
Daugherty, S.A. Sullivan, M.J. Rosovitz, M.L. Gwinn, L. Zhou, D.J. Schneider, S.W.
Cartinhour, W.C. Nelson, J. Weidman, K. Watkins, K. Tran, H. Khouri, E.A. Pierson,
L.S. Pierson III, L.S. Thomashow, J.E. Loper, Complete genome sequence of the plant
commensal Pseudomonas ﬂuorescens Pf-5, Nature Biotechnol. 23 (2005) 873–878.
[23] M. Morikawa, H. Daido, T. Takao, S. Murata, Y. Shimonishi, T. Imanaka, A new
lipopeptide biosurfactant produced by Arthrobacter sp. strain MIS38, J. Bacteriol.
175 (1993) 6459–6466.
[24] N. Vodovar, D. Vallenet, S. Cruveiller, Z. Rouy, V. Barbe, C. Acosta, L. Cattolico, C. Jubin,
A. Lajus, B. Segurens, B. Vacherie, P.Wincker, J.Weissenbach, B. Lemaitre, C.Médigue,
F. Boccard, Complete genome sequence of the entomopathogenic and metabolically
versatile soil bacterium Pseudomonas entomophila, Nature Biotechnol. 24 (2006)
673–679.
[25] J.T. de Souza, M. de Boer, P. de Waard, T.A. van Beek, J.M. Raaijmakers, Biochemical,
genetic, and zoosporicidal properties of cyclic lipopeptides surfactants produced by
Pseudomonas ﬂuorescens, Appl. Environ. Microbiol. 69 (2003) 7161–7172.
[26] I. de Bruijn, M.J. de Kock, P. deWaard, T.A. van Beek, J.M. Raaijmakers, Massetolide
A biosynthesis in Pseudomonas ﬂuorescens, J. Bacteriol. 190 (2008) 2777–2789.
[27] R.H. Baltz, V. Miao, S.K. Wrigley, Natural products to drugs: daptomycin and
related lipopeptide antibiotics, Nat. Prod. Rep. 22 (2005) 717–741.
[28] K. Christ, H.H. Rüttinger, M. Höpfner, U. Rothe, G. Bendas, The detection of UV-
induced membrane damages by a combination of two biosensor techniques,
Photochem. Photobiol. 81 (2005) 1417–1423.
[29] K. Christ, I. Wiedemann, U. Bakowsky, H.G. Sahl, G. Bendas, The role of lipid II in
membrane binding of and pore formation by nisin analyzed by two combined
biosensor techniques, BBA 1768 (2007) 694–704.[30] K. Amada, M. Haruki, T. Imanaka, M. Morikawa, S. Kanaya, Overproduction in
Escherichia coli, puriﬁcation and characterization of a family I.3 lipase from
Pseudomonas sp. MIS38, BBA 1478 (2000) 201–210.
[31] K. Washio, S.P. Lim, N. Roongsawang, M. Morikawa, Identiﬁcation and character-
ization of the genes responsible for the production of the cyclic lipopeptides
arthrofactin by Pseudomonas sp. MIS38, Biosci. Biotechnol. Biochem. 74 (2010)
992–999.
[32] M. Sareen, G.K. Khuller, Phospholipids of ethambutol-susceptible and resistent
strains of Mycobacterium smegmatis, J. Biosc. 13 (1988) 243–248.
[33] T. Johnsson, P. Nikkila, L. Toivonen, H. Rosenqvist, S. Laakso, Cellular fatty acids
proﬁles of Lactobacillus and Lactococcus strains in relation to the oleic acid content
of the cultivation medium, Appl. Environment. Microbiol. 61 (1995) 4497–4499.
[34] H. Tsuchiya, M. Sato, M. Kato, I. Namikawa, T. Hayashi, M. Tatsumi, N. Takagi, High-
Performance Liquid Chromatographic Analysis of Bacterial Fatty Acid Composition
for Chemotaxonomic Characterization of Oral Streptococci, J. Clin. Microbiol. 24
(86) (1986) 81–85.
[35] B.J. Wilkinson, M.R. Morman, D.C. White, Phospholipid composition and
metabolism of Micrococcus denitriﬁcans, J. Bacteriol. 112 (1972) 1288–1294.
[36] M.L. Hutchison, M.A. Tester, D.C. Gross, Role of biosurfactant and ion channel-
forming activities of syringomycin in transmembrane ion ﬂux: a model for the
mechanism of action in the plant-pathogen interaction, Mol. Plant Microbe
Interact. 8 (1995) 610–620.
[37] M. Dalla Serra, G. Fagiuoli, P. Nordera, I. Bernhart, C. Della Volpe, D. Di Giorgio, A.
Ballio, G. Menestrina, The interaction of lipodepsipeptide toxins from Pseudomonas
syringae pv. syringae with biological and model membranes: a comparison of
syringotoxin, syringomycin, and two syringopeptins, Mol. PlantMicrobe Interact. 12
(1999) 391–400.
[38] O. Nybroe, J. Sørensen, Production of cyclic lipopeptides by ﬂuorescent
pseudomonads, in: J.L. Ramos (Ed.), Pseudomonas, Biosynthesis of Macromole-
cules and Molecular Metabolism, Kluwer Academic/Plenum Publishers, New
York, 2004, pp. 147–172.
[39] L. Wang, R.A. Slayden, C.E. Barry III, J. Liu, Cell wall structure of a mutant of
Mycobacterium smegmatis defective in the biosynthesis of mycolic acids, J. Biol.
Chem. 275 (2000) 7224–7229.
[40] R. Mukherjee, M. Gomez, N. Jayaraman, I. Smith, D. Chatterji, Hyperglycosylation
of glcopeptidolipid of Mycobacterium smegmatis under nutrient starvation:
structural studies, Microbiology 151 (2005) 2385–2392.
[41] K. Reder-Christ, H. Falkenstein-Paul, G. Klocek, S. Al-Kaddah, U. Bakowsky, G.
Bendas, Model membrane approaches to determine the role of calcium for the
antimicrobial activity of friulimicin, Int. J. Antimicrob. Agents 37 (2011) 256–260.
[42] G. Agner, Y.A. Kaulin, P.A. Gurnev, Z. Szabo, L.V. Schagina, J.Y. Takemoto, K. Blasko,
Membrane-permeabilizing activities of cyclic lipodepsipeptides, syringopeptin
22A and syringomycin E from Pseudomonas syringae pv. syringae in human red
blood cells and in bilayer lipid membranes, Bioelectrochemistry 52 (2000)
161–167.
[43] J.E. van de Mortel, H. Tran, F. Govers, J.M. Raaijmakers, Cellular responses of the
Late Blight pathogen Phytophthora infestans to cyclic lipopeptide surfactants and
their dependence on G proteins, Appl. Environ. Microbiol. 75 (2009) 4950–4957.
[44] S. Szabó, P. Gróf, L.V. Schagina, P.A. Gurnev, J.Y. Takemoto, E. Mátyus, K. Blaskó,
Syringotoxin pore formation and inactivation in human red blood cell and model
bilayers lipid membranes, BBA 1567 (2002) 143–149.
[45] K. Blasko, L.V. Schagina, G. Agner, Y.A. Kaulin, J.Y. Takemoto, Membrane sterol
composition modulates the pore forming activity of syringomycin E in human red
blood cells, BBA 1373 (1998) 163–169.
[46] G. Agner, Y.A. Kaulin, L.V. Schagina, J.Y. Takemoto, K. Blasko, Effect of temperature
on the formation and inactivation of syringomycin E pores in human red blood
cells and bimolecular lipid membranes, BBA 1466 (2000) 79–86.
[47] D. Di Giorgio, L. Camoni, C. Marchiafava, A. Ballio, Biological activities of
pseudomycin A, a lipodepsinonapeptide from Pseudomonas syringae MSU 16H,
Phytochemistry 45 (1997) 1385–1391.
[48] Y.A. Kaulin, L.V. Schagina, S.M. Bezrukov, V.V. Malev, A.M. Feigin, J.Y. Takemoto,
J.H. Teeter, J.G. Brand, Cluster organization of ion channels formed by the
antibiotic syringomycin E in bilayer lipid membranes, Biophys. J. 74 (1998)
2918–2925.
[49] J.D. Sheppard, C. Jumarie, D.G. Cooper, R. Laprade, Ionic channels induced by
surfactin in planar lipid bilayer membranes, BBA 1064 (1991) 13–23.
[50] S. de Oliveira, C. Saldanha, An overview about erythrocyte membrane, Clin.
Hemorheol. Microcirc. 44 (2010) 63–74.
[51] S. Thennarasu, D.K. Lee, A. Tan, U. Prasad Kari, A. Ramamoorthy, Antimicrobial
activity and membrane selective interactions of a synthetic lipopeptide MSI-843,
BBA 1711 (2005) 49–58.
[52] H. Maki, K. Miura, Y. Yamano, Katanosin B and Plusbacin A3, inhibitors of
peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus, Antimi-
crob. Agents Chemother. 45 (2001) 1823–1827.
[53] H. Brötz-Oesterhelt, D. Beyer, H.-P. Kroll, R. Endermann, C. Ladel, W. Schroeder,
B. Hinzen, S. Raddatz, H. Paulsen, K. Henninger, J.E. Bandow, H.-G. Sahl, H.
Labischinski, Dysregulation of bacterial proteolytic machinery by a new class of
antibiotics, Nat. Med. 11 (2005) 1082–1087.
[54] S. Thennarasu, D.K. Lee, A. Poon, K.E. Kawulka, J.C. Vederas, A. Ramamoorthy,
Membrane permeabilization, orientation, and antimicrobial mechanism of
subtilosin A, Chem. Phys. Lipids 137 (2005) 38–51.
